fda removes semaglutide shortage list 2025 Injections and the Federal judge upholds FDA's removal
Description
BioNxts ODF platform aims to offer a needle-free, rapidly dissolving alternative that can simplify administration and improve user experience, particularly for patients managing chronic conditions like diabetes and obesity
Most patients begin to see results in the first few weeks after starting treatment
The Phase 2 trial included DEXA scans to measure changes in fat mass and lean mass
After combining effect size, the meta-analysis showed that mean difference (MD) = 2.16, 95% confidence interval (95% CI): 1.452.88 and p 0.05), indicating no significant difference in the results
